Is Fennec Pharmaceuticals Inc. (FRX.TO) a Buy, Sell, or Hold?
TSX : FRX.TO
Fennec Pharmaceuticals Inc.
$14.22 CAD
$0 (0.0%)
- Volume
- 16
- Average Volume
- 1.17K
- Market Capitalization
- $430.39M
- P/E Ratio
- -33.60
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $15.48
- Year Low
- $7.59
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $6.98
Company Overview
TSX
Jeffrey S. Hackman
Biotechnology
Healthcare
FRX.TO
35
US
CAD
Liquidity Metrics
0.00
6.98
6.78
4.19
0.00
Sales & Valuation
$44.64M
5.78
9.41
-51.06
-0.17
Profitability
-$0.34
-$9.74M
-16.42%
-16.22%
-54.75%
-11.66%
P/E Metrics
-33.60
-2.41
-2.41
Analyst Price Target & Rating
1/5
7 Analysts
%
Financial Health Scores
2.33
5/9
$57.15M
$71.64M
$34.06M
-$5.49M
Key Metrics (TTM)
No key metrics data available.
Company Executives
| Name | Title |
|---|---|
| Jeffrey S. Hackman | Chief Executive Officer & Director |
| Mark Gowland | Controller |
| Christiana Cioffi | Chief Strategy Officer |
| Terry Evans | Chief Commercial Officer |
| Robert C. Andrade | Chief Financial Officer |
| Pierre S. Sayad | Chief Medical Officer |
| Lei Fang | President of Pharstat Inc |
Poll Results
No votes yet today — be the first to share your view!
About Fennec Pharmaceuticals Inc. (TSX:FRX.TO) Stock
Fennec Pharmaceuticals Inc., a biopharmaceutical firm established in 1996, operates from its base in Research Triangle Park, North Carolina. The company's lead investigational compound, PEDMARK, is a sodium thiosulfate formulation currently undergoing clinical development. This product candidate is specifically engineered to protect young cancer patients from platinum-induced ototoxicity, a form of hearing loss caused by chemotherapy. Previously known as Adherex Technologies Inc., the company officially rebranded to Fennec Pharmaceuticals Inc. in September 2014. ...
Frequently Asked Questions
-
What is the current Fennec Pharmaceuticals Inc. (FRX.TO) stock price?
-
Fennec Pharmaceuticals Inc.(TSX:FRX.TO) stock price is $14.22 in the last trading session. During the trading session, FRX.TO stock reached the peak price of $15.48 while $7.59 was the lowest point it dropped to. The percentage change in FRX.TO stock occurred in the recent session was 0.0% while the dollar amount for the price change in FRX.TO stock was $0.
-
FRX.TO's industry and sector of operation?
-
The TSX listed FRX.TO is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of FRX.TO?
-
Jeffrey S. Hackman | Chief Executive Officer & Director
Mark Gowland | Controller
Christiana Cioffi | Chief Strategy Officer
Terry Evans | Chief Commercial Officer
Robert C. Andrade | Chief Financial Officer -
How many employees does FRX.TO have?
-
Number of FRX.TO employees currently stands at 35. FRX.TO operates from 68 TW Alexander Drive, Research Triangle Park, NC 27709, US.
-
Link for FRX.TO official website?
-
Official Website of FRX.TO is: https://www.fennecpharma.com
-
How do I contact FRX.TO?
-
FRX.TO could be contacted at phone #919 636 4530 and can also be accessed through its website. FRX.TO operates from 68 TW Alexander Drive, Research Triangle Park, NC 27709, US.
-
How many shares of FRX.TO are traded daily?
-
The average number of FRX.TO shares traded daily for last 3 months was 1.17K.
-
What is the market cap of FRX.TO currently?
-
The market value of FRX.TO currently stands at $430.39M with its latest stock price at $14.22